Safety and antigenicity of influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine in young seronegative children
Identifieur interne : 002B90 ( Main/Exploration ); précédent : 002B89; suivant : 002B91Safety and antigenicity of influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine in young seronegative children
Auteurs : Peter F. Wright [États-Unis] ; Sarah H. Sell [États-Unis] ; Tatsuhiko Shinozaki [États-Unis] ; Juliette Thompson [États-Unis] ; David T. Karzon [États-Unis]Source :
- The Journal of Pediatrics [ 0022-3476 ] ; 1975.
English descriptors
- Teeft :
- Adult volunteers, Anab, Antibody response, Antineuraminidase antibody, Attenuated, Attenuated vaccines, Brian murphy, Broader protection, Clinical findings, Clinical illness, Clinical observations, Clinical trials, Control children, Control group, Greater rise, Hemagglutinin, High titer, Hong kong, Infectious disease, Infectious diseases, Influenza, Influenza kong, Influenza vaccine, Influenza vaccines, Influenza virus, Intranasal administration, Mutant, Nasal washes, National institute, Natural influenza, Negative children, Neuraminidase, Nursing personnel, Older children, Other viruses, Pediatrics december, Respiratory syncytial virus, Restrictive temperature, Revertant, Revertant influenza, Revertant virus, Rhinorrhea, Serologic response, Seronegative, Seronegative children, Vaccine, Vaccine administration, Vaccine clinic, Vaccine trials, Vaccine virus, Vaccinee, Virus, Young child, Young children, Young seronegative child, Younger children.
Abstract
Influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine was administered intranasally to 18 seronegative children 14 to 32 months of age. Fourteen children, 78%, shed influenza A/Hong Kong virus for a mean of eight days following vaccination. Sixteen children, 89%, experienced a fourfold or greater rise in hemagglutination-inhibition antibody. Some children appeared to experience a febrile reaction to the vaccine although interpretation of this data was complicated by intercurrent illness. These findings demonstrate that influenza A ts-1 [E] replicates more readily in the young seronegative child than in the HAI negative adult. In addition, the temperature-sensitive marker of the vaccine was not genetically stable in four of the vaccinated children. Careful evaluation of any future live respiratory viral vaccines needs to be undertaken in the young seronegative child before the vaccine's safety is fully established.
Url:
DOI: 10.1016/S0022-3476(75)80123-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001351
- to stream Istex, to step Curation: 001351
- to stream Istex, to step Checkpoint: 001752
- to stream Main, to step Merge: 002D62
- to stream Main, to step Curation: 002B90
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and antigenicity of influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine in young seronegative children</title><author><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name></author><author><name sortKey="Sell, Sarah H" sort="Sell, Sarah H" uniqKey="Sell S" first="Sarah H." last="Sell">Sarah H. Sell</name></author><author><name sortKey="Shinozaki, Tatsuhiko" sort="Shinozaki, Tatsuhiko" uniqKey="Shinozaki T" first="Tatsuhiko" last="Shinozaki">Tatsuhiko Shinozaki</name></author><author><name sortKey="Thompson, Juliette" sort="Thompson, Juliette" uniqKey="Thompson J" first="Juliette" last="Thompson">Juliette Thompson</name></author><author><name sortKey="Karzon, David T" sort="Karzon, David T" uniqKey="Karzon D" first="David T." last="Karzon">David T. Karzon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7679670C49CB01EFE1F6A28E928994B2A2A72476</idno><date when="1975" year="1975">1975</date><idno type="doi">10.1016/S0022-3476(75)80123-5</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-LC57QCVC-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001351</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001351</idno><idno type="wicri:Area/Istex/Curation">001351</idno><idno type="wicri:Area/Istex/Checkpoint">001752</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001752</idno><idno type="wicri:doubleKey">0022-3476:1975:Wright P:safety:and:antigenicity</idno><idno type="wicri:Area/Main/Merge">002D62</idno><idno type="wicri:Area/Main/Curation">002B90</idno><idno type="wicri:Area/Main/Exploration">002B90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety and antigenicity of influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine in young seronegative children</title><author><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author><author><name sortKey="Sell, Sarah H" sort="Sell, Sarah H" uniqKey="Sell S" first="Sarah H." last="Sell">Sarah H. Sell</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author><author><name sortKey="Shinozaki, Tatsuhiko" sort="Shinozaki, Tatsuhiko" uniqKey="Shinozaki T" first="Tatsuhiko" last="Shinozaki">Tatsuhiko Shinozaki</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Juliette" sort="Thompson, Juliette" uniqKey="Thompson J" first="Juliette" last="Thompson">Juliette Thompson</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author><author><name sortKey="Karzon, David T" sort="Karzon, David T" uniqKey="Karzon D" first="David T." last="Karzon">David T. Karzon</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville</wicri:regionArea><wicri:noRegion>Nashville</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Pediatrics</title><title level="j" type="abbrev">YMPD</title><idno type="ISSN">0022-3476</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1975">1975</date><biblScope unit="volume">87</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="supplement">P2</biblScope><biblScope unit="page" from="1109">1109</biblScope><biblScope unit="page" to="1116">1116</biblScope></imprint><idno type="ISSN">0022-3476</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adult volunteers</term><term>Anab</term><term>Antibody response</term><term>Antineuraminidase antibody</term><term>Attenuated</term><term>Attenuated vaccines</term><term>Brian murphy</term><term>Broader protection</term><term>Clinical findings</term><term>Clinical illness</term><term>Clinical observations</term><term>Clinical trials</term><term>Control children</term><term>Control group</term><term>Greater rise</term><term>Hemagglutinin</term><term>High titer</term><term>Hong kong</term><term>Infectious disease</term><term>Infectious diseases</term><term>Influenza</term><term>Influenza kong</term><term>Influenza vaccine</term><term>Influenza vaccines</term><term>Influenza virus</term><term>Intranasal administration</term><term>Mutant</term><term>Nasal washes</term><term>National institute</term><term>Natural influenza</term><term>Negative children</term><term>Neuraminidase</term><term>Nursing personnel</term><term>Older children</term><term>Other viruses</term><term>Pediatrics december</term><term>Respiratory syncytial virus</term><term>Restrictive temperature</term><term>Revertant</term><term>Revertant influenza</term><term>Revertant virus</term><term>Rhinorrhea</term><term>Serologic response</term><term>Seronegative</term><term>Seronegative children</term><term>Vaccine</term><term>Vaccine administration</term><term>Vaccine clinic</term><term>Vaccine trials</term><term>Vaccine virus</term><term>Vaccinee</term><term>Virus</term><term>Young child</term><term>Young children</term><term>Young seronegative child</term><term>Younger children</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine was administered intranasally to 18 seronegative children 14 to 32 months of age. Fourteen children, 78%, shed influenza A/Hong Kong virus for a mean of eight days following vaccination. Sixteen children, 89%, experienced a fourfold or greater rise in hemagglutination-inhibition antibody. Some children appeared to experience a febrile reaction to the vaccine although interpretation of this data was complicated by intercurrent illness. These findings demonstrate that influenza A ts-1 [E] replicates more readily in the young seronegative child than in the HAI negative adult. In addition, the temperature-sensitive marker of the vaccine was not genetically stable in four of the vaccinated children. Careful evaluation of any future live respiratory viral vaccines needs to be undertaken in the young seronegative child before the vaccine's safety is fully established.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Wright, Peter F" sort="Wright, Peter F" uniqKey="Wright P" first="Peter F." last="Wright">Peter F. Wright</name></noRegion><name sortKey="Karzon, David T" sort="Karzon, David T" uniqKey="Karzon D" first="David T." last="Karzon">David T. Karzon</name><name sortKey="Sell, Sarah H" sort="Sell, Sarah H" uniqKey="Sell S" first="Sarah H." last="Sell">Sarah H. Sell</name><name sortKey="Shinozaki, Tatsuhiko" sort="Shinozaki, Tatsuhiko" uniqKey="Shinozaki T" first="Tatsuhiko" last="Shinozaki">Tatsuhiko Shinozaki</name><name sortKey="Thompson, Juliette" sort="Thompson, Juliette" uniqKey="Thompson J" first="Juliette" last="Thompson">Juliette Thompson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7679670C49CB01EFE1F6A28E928994B2A2A72476
|texte= Safety and antigenicity of influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine in young seronegative children
}}
| This area was generated with Dilib version V0.6.33. |  |